Aripiprazole for refractory catatonic schizophrenia – A case report

Background: Catatonia is a disorder of varying aetiology characterised by psychomotor disturbance, mutism, negativism, catalepsy, echo phenomenon. Schizophrenia accounts for 10-15% of cases. Atypical antipsychotics are used in treatment resistant cases, of which aripiprazole has a unique D2 partial...

Full description

Bibliographic Details
Published in:	Archives of Mental Health
Main Authors:	Saisudha N V Gorthi, Prasanna N Kumar
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2015-01-01
Subjects:	aripiprazole catatonia catatonic schizophrenia
Online Access:	http://www.amhonline.org/article.asp?issn=2589-9171;year=2015;volume=16;issue=1;spage=96;epage=97;aulast=Gorthi;type=0

Similar Items

Variants and factors of catatonic syndrome pathomorphosis in the structure of endogenous catatonia
by: D. M. Safonov
Published: (2021-11-01)

Wernicke encephalopathy complicating catatonic schizophrenia
by: C. Rihab, et al.
Published: (2021-04-01)

Catatonia in ICD-11
by: Jonathan P. Rogers, et al.
Published: (2025-04-01)

Case Report: Catatonic Stupor in Behavioral Variant Frontotemporal Dementia
by: Gustavo Campos de França, et al.
Published: (2022-01-01)

The Role of Metabolic Disorders in the Development of Waxy Flexibility in Patients with Catatonic Schizophrenia
by: Reza Abdollahi
Published: (2025-06-01)

Non catatonic mutism in schizophrenia- a case report and discussion
by: Srilakshmi Pingali, et al.
Published: (2013-01-01)

Refeeding syndrome in catatonic schizophrenia
by: Supriya Agarwal, et al.
Published: (2019-01-01)

Prevalence of Catatonic Schizophrenia Symptoms in a Psychiatric Hospital: A Retrospective Study
by: Javad Setare, et al.
Published: (2018-08-01)

On the problem of the catatonic disorders taxonomy
by: V. Lobanova, et al.
Published: (2022-06-01)

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
by: Saki Hattori, et al.
Published: (2023-03-01)

Comparative effectiveness of aripiprazole and olanzapine on neurocognitive profile of patients with schizophrenia
by: Sanya Sharma, et al.
Published: (2023-10-01)

Schizophrenia: effects of aripiprazole in metabolic syndrome
by: Deborah Galvão Coelho da Silva, et al.
Published: (2019-11-01)

Increased Ribosome Biogenesis and Increased Oxidative Stress in Blood Leukocytes of Patients With Catatonic Schizophrenia Compared With Paranoid Schizophrenia
by: Elisaveta S. Ershova, et al.
Published: (2025-08-01)

Catatonia in autism spectrum disorders: A systematic review and meta-analysis
by: J. Vaquerizo-Serrano, et al.
Published: (2022-01-01)

Determination of Changes in Blood Biomarker Levels in Antipsychotic Polypharmacy and Aripiprazole Monotherapy in Patients With Long-term Schizophrenia
by: Venus Vatankhah, et al.
Published: (2019-12-01)

Effectiveness and safety of aripiprazole oral solution in the acute treatment of schizophrenia in Chinese patients
by: Zhen Mao, et al.
Published: (2024-12-01)

Dynamics of mental state and prolactin levels in patients with chronic schizophrenia during aripiprazole therapy
by: L. N. Gorobets, et al.
Published: (2023-10-01)

Catatonic Futures and Post-Apocalyptic Capital
by: Tomas Vergara
Published: (2020-10-01)

Hyperprolactinaemia and menstrual irregularity emerging in association with risperidone use and treated with aripiprazole in an adolescent diagnosed with schizophrenia: a case report
by: Şermin Bilgen Ulgar, et al.
Published: (2018-10-01)

Gayet–Wernicke encephalopathy: a complication not to be overlooked in patients with catatonic schizophrenia
by: Neila Messedi, et al.
Published: (2023-04-01)

Appropriate use of single-dose injectable aripiprazole lauroxil in the treatment of schizophrenia
by: Rachael C. Davis, BS, et al.
Published: (2024-12-01)

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
by: Kishi T, et al.
Published: (2016-11-01)

Comparative cardiovascular outcomes of aripiprazole vs. risperidone in patients with type 2 diabetes and schizophrenia: a retrospective cohort study
by: Yi-Ting Yeh, et al.
Published: (2025-07-01)

Efficacy of aripiprazole combined with olanzapine for hospitalized male patients with schizophrenia and its effect on metabolic syndrome
by: Liu Shunhua, et al.
Published: (2024-06-01)

A systematic review and meta-analysis of the effects of combined aripiprazole on glycolipid metabolism in schizophrenia
by: Tianbao Wei, et al.
Published: (2025-01-01)

Long-term effectiveness of aripiprazole once monthly on functioning and quality of life in schizophrenia: results of year 2 of the ReLiAM study
by: Marc-André Roy, et al.
Published: (2024-11-01)

Effects of aripiprazole on prolactin levels and differences in effectiveness in patients with schizophrenia: a post-hoc analysis of the real-world data of a multicenter study
by: Qian Li, et al.
Published: (2024-08-01)

Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review
by: Kunal Maini, et al.
Published: (2021-07-01)

Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study
by: José Manuel Olivares, et al.
Published: (2021-01-01)

Clinical experience with the new double aripiprazole depot regime in a psychiatric hospitalization unit
by: Á. Moleón Ruiz, et al.
Published: (2022-06-01)

Comparision of aripiprazole and risperidone in improving psychiatric symptoms among chronic schizophrenia patients
by: Wang Jianfeng, et al.
Published: (2025-04-01)

The Impact of Adjunctive Aripiprazole on Olanzapine‐Induced Metabolic Adverse Effects in Patients With Schizophrenia: A Systematic Review
by: Stephen Simmons, et al.
Published: (2025-09-01)

Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole
by: Peters-Strickland T, et al.
Published: (2016-10-01)

Augmentation of aripiprazole by flupenthixol decanoate in poorly responsive schizophrenia: a randomized clinical study
by: Saeed Shoja Shafti
Published: (2017-07-01)

Single- and multiple-dose pharmacokinetics, safety, and tolerability of Aripiprazole once-monthly, long-acting intramuscular injection for Chinese adults with schizophrenia
by: Fang Dong, et al.
Published: (2025-10-01)

Effects of Aripiprazole on Olanzapine Population Pharmacokinetics and Initial Dosage Optimization in Schizophrenia Patients
by: Zhang C, et al.
Published: (2024-03-01)

Idiopathic catatonic syndrome in a young male with no prior psychiatric history: a case report
by: Jennifer L. Zick, et al.
Published: (2023-05-01)

Variations in Sleep Architecture among Different Subtypes of Schizophrenia: A Cross-sectional Study
by: Sagarika Ray, et al.
Published: (2023-12-01)

Cognitive Impairment in Schizophrenia, Neurotransmitters and the New Atypical Antipsychotic Aripiprazole
by: Topolov Mariyan K., et al.
Published: (2016-03-01)

Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study
by: Howard C. Margolese, et al.
Published: (2022-12-01)